Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis

References

• Cushing HW. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 1932;50:137–195.
   Google Scholar
• Hahn TJ. Corticosteroid-induced osteopenia. Arch Intern Med. 1978;138:882–885.
   PubMedGoogle Scholar
• Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983;309(5):265–268.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.
   PubMed Web of Science ®Google Scholar
• Amiche MA, Albaum JM, Tadrous M, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016;27(5):1709–1718.
   PubMed Web of Science ®Google Scholar
• Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7–16.
   PubMed Web of Science ®Google Scholar
• Hardy RS, Zhou H, Seibel MJ et al. Glucocorticoids and Bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev 2018;39(5):519–548.
   PubMed Web of Science ®Google Scholar
• Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019;30(6):1145–1156.
   PubMed Web of Science ®Google Scholar
• Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol. 2009;201(3):309–320.
   PubMed Web of Science ®Google Scholar
• Briot K, Geusens P, Em Bultink I et al. Inflammatory diseases and bone fragility. Osteoporos Int. 2017;28(12):3301–3314.
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Lix LM, Morin SN, et al. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol. 2013;40(10):1736–1741.
   PubMed Web of Science ®Google Scholar
• Trijau S, de Lamotte G, Pradel V, et al. Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD Open 2016;2(2):e000249.
   PubMed Web of Science ®Google Scholar
• Amiche MA, Lévesque LE, Gomes T, et al. Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res. 2018;33(3):419–429.
   PubMed Web of Science ®Google Scholar
• Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011;50(11):1982–1990.
   PubMed Web of Science ®Google Scholar
• Overman RA, Yeh J-Y, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294–298.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–1389.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420–426.
   Web of Science ®Google Scholar
• Amiche MA, Abtahi S, Driessen JHM, et al. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos. 2018;13(1):30.
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Wade SW, Adler RA, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27(11):3239–3249.
   PubMed Web of Science ®Google Scholar
• Lu P-C, Yang Y-H, Guo S-E, et al. Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease-a nationwide retrospective study. Osteoporos Int. 2017; 28(1):359–367.
   PubMed Web of Science ®Google Scholar
• Paskins Z, Whittle R, Sultan AA, et al. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med. 2018;16(1):4.
   PubMedGoogle Scholar
• Sutter SA, Stein EM. The skeletal effects of inhaled glucocorticoids. Curr Osteoporos Rep. 2016;14(3):106–113.
   PubMed Web of Science ®Google Scholar
• Caramori G, Ruggeri P, Arpinelli F, et al. Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature. Int J Chron Obstruct Pulmon Dis. 2019;14:1085–1097.
   PubMed Web of Science ®Google Scholar
• Hubbard R, Tattersfield A, Smith C, et al. Use of inhaled corticosteroids and the risk of fracture. Chest. 2006; 130(4):1082–1088.
   PubMed Web of Science ®Google Scholar
• Gonçalves PA, Dos Santos Neves R, Neto LV, et al. Inhaled glucocorticoids are associated with vertebral fractures in COPD patients. J Bone Miner Metab. 2018;36(4):454–461.
   PubMed Web of Science ®Google Scholar
• Jones A, Fay JK, Burr ML, et al. Cochrane airways group. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002(1): CD003537.
   PubMedGoogle Scholar
• Lane NE. Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments. Curr Osteoporos Rep. 2019;17(1):1–7.
   PubMed Web of Science ®Google Scholar
• Hachemi Y, Rapp AE, Picke AK et al. Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture. J Mol Endocrinol. 2018; 61(1):R75–R90.
   PubMed Web of Science ®Google Scholar
• Jia D, O’Brien CA, Stewart SA et al. Glucocorticoids acts directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006;147(12):5592–5599.
   PubMed Web of Science ®Google Scholar
• Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta,C/EBPdelta, and glucocorticoids. Mol Cell Biol. 1996;16(8):4128–4136.
   PubMed Web of Science ®Google Scholar
• Guanabens N, Gifre L, Peris P. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid induced osteoporosis. Curr Osteoporos Rep. 2014;12(1):90–97.
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Tanabe M, Kawate H et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005;329(1):177–181.
   PubMed Web of Science ®Google Scholar
• Wang L, Heckmann BL, Yang X et al. Osteoblast autophagy in glucocorticoid-induced osteoporosis. J Cell Physiol. 2019;234(4):3207–3215.
   PubMed Web of Science ®Google Scholar
• Almeida M, Han L, Ambrogini E, et al. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;286(52):44326–44335.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol. 2013;9(5):265–276.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Formenti AM, Adler RA et al. Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine. 2016;54(3):603–611.
   PubMed Web of Science ®Google Scholar
• Kauh E, Mixson L, Malice MP, et al. Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals. Eur J Endocrinol. 2012;166(3):459–467.
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835–1841.
   PubMed Web of Science ®Google Scholar
• Dalle Carbonare L, Arlot ME, Chavassieux PM et al. Comparison of trabecular bone microarchitecture and remodelling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001;16(1):97–103.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48(11):3224–3229.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Francucci CM, Scillitani A. Densitometry in glucocorticoid-induced osteoporosis. J Endocrinol Invest. 2008;31(7):33–37.
   PubMedGoogle Scholar
• Chiodini I, Torlontano M, Carnevale V, et al. Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest. 2008; 31(3):267–276.
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.
   PubMed Web of Science ®Google Scholar
• Sato AY, Richardson D, Cregor M, et al. Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology. 2017;158(3):664–677.
   PubMed Web of Science ®Google Scholar
• Karsenty G, Olson EN. Bone and muscle endocrine functions: unexpected paradigms of inter-organ communication. Cell. 2016;164(6):1248–1256.
   PubMed Web of Science ®Google Scholar
• Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a reexamination of the evidence. J Clin Endocrinol Metab. 2002;87(9):4033–4041.
   PubMed Web of Science ®Google Scholar
• Gennari C. Differential effect of glucocorticoids on calcium absorption and bone mass. Br J Rheumatol. 1993;32(2):11–14.
   PubMedGoogle Scholar
• Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011 May;96(5):1223–1236.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016 Jul;4(7):611–629.
   PubMed Web of Science ®Google Scholar
• Eller-Vainicher C, Falchetti A, Gennari L, et al. Diagnosis of endocrine diseases: evaluation of bone fragility in endocrine disorders. Eur J Endocrinol. 2019; EJE-18-0991.R1.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Mascia ML, Muscarella S, et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007;147(8):541–548.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Albani A, Ambrogio AG, et al. Six controversial issues on subclinical Cushing’s syndrome. Endocrine. 2017;56(2):262–266.
   PubMed Web of Science ®Google Scholar
• Tauchmanovà L, Pivonello R, Di Somma C et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab. 2006 91(5):1779–1784.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Vainicher CE, Morelli V, et al. Mechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol. 2016;175(6):R265–R282.
   PubMedGoogle Scholar
• Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593–5602.
   PubMed Web of Science ®Google Scholar
• Eller-Vainicher C, Morelli V, Ulivieri FM, et al. Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J Bone Miner Res. 2012; 27(10):2223–2230.
   PubMed Web of Science ®Google Scholar
• Webb SM, Valassi E. Morbidity of Cushing’s syndrome and impact of treatment. Endocrinol Metab Clin North Am. 2018; 47(2):299–311.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19 (6):893–899.
   PubMed Web of Science ®Google Scholar
• Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018;379(26):2547–2556.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–816.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 american college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and non vertebral fractures: results for the MORE trial. Bone 2003;33(4):522–532.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab. 2009;94(9):3207–3214.
   PubMed Web of Science ®Google Scholar
• Hans D, Goertzen AL, Krieg MA, et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density; the manitoba study. J Bone Miner Res. 2001;26(11): 2762–2769.
   Google Scholar
• Florez H, Hernández-Rodríguez J, Muxi A, et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology (Oxford). 2019; kez464. DOI:10.1093/rheumatology/kez464
   Google Scholar
• Saag KG, Agnusdei D, Hans D et al. Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide. Arthritis Rheum. 2016;68(9):2122–2128.
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257–2276.
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2012;7:25–30.
   PubMedGoogle Scholar
• Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese society for bone and mineral research: 2014 update. J Bone Miner Metab. 2014; 32(4):337–350.
   PubMed Web of Science ®Google Scholar
• Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Lindholm J, Jørgensen JO, et al. Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol. 2002;146(1):51–56.
   PubMed Web of Science ®Google Scholar
• Scillitani A, Mazziotti G, Di Somma C, et al. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int. 2014;25(2):441–446.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Viti R, Coletti F, et al. Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin Endocrinol (Oxf). 2009;70(2):208–213.
   PubMed Web of Science ®Google Scholar
• Salcuni AS, Morelli V, Eller Vainicher C, et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur J Endocrinol. 2016 174(3):261–269.
   PubMed Web of Science ®Google Scholar
• Morelli V, Eller-Vainicher C, Palmieri S, et al. Prediction of vertebral fractures in patients with monolateral adrenal incidentalomas. J Clin Endocrinol Metab. 2016;101(7):2768–2775.
   PubMed Web of Science ®Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Endocrine society. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930.
   PubMed Web of Science ®Google Scholar
• Troy KL, Mancuso ME, Butler TA, et al. Exercise early and often: effects of physical activity and exercise on women’s bone health. Int J Environ Res Public Health. 2018;15(5): E878.
   PubMed Web of Science ®Google Scholar
• Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ. 2015;351:h3783.
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Crockett JC, Coxon FP, et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49(1):34–41.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363–1374.
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the preventionand treatment of glucocorticoid induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med. 1998;339(5):292–299.
   PubMed Web of Science ®Google Scholar
• Adachi JD, Saag KG, Delmas PD, et al. Two-year effects ofalendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202–211.
   PubMedGoogle Scholar
• Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009;36(8):1705–1714.
   PubMed Web of Science ®Google Scholar
• Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum. 1999;42(11):2309–2318.
   PubMed Web of Science ®Google Scholar
• Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res. 2000;15(6):1006–1013.
   PubMed Web of Science ®Google Scholar
• Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277–285.
   PubMed Web of Science ®Google Scholar
• Reid DM, Adami S, Devogelaer JP, et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001;69(4):242–247.
   PubMed Web of Science ®Google Scholar
• Axelsson KF, Nilsson AG, Wedel H, et al. Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 2017;318(2):146–155.
   PubMed Web of Science ®Google Scholar
• Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14(10):801–807.
   PubMed Web of Science ®Google Scholar
• Shin K, Park S-H, Park W et al. Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double blinded randomized placebo-controlled investigator-initiated trial Clin Ther. 2017;39(2):268–278.
   PubMed Web of Science ®Google Scholar
• Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res. 2009;24(7):1335–1344.
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–1263.
   PubMed Web of Science ®Google Scholar
• Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10:CD001347.
   PubMedGoogle Scholar
• Horton DB, Haynes K, Denburg MR, et al. Oral glucocorticoid use and osteonecrosis in children and adults with chronic inflammatory diseases: a population-based cohort study. BMJ Open. 2017;7:e016788.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2014;29:1–23.
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–831.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.
   PubMed Web of Science ®Google Scholar
• Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–454.
   PubMed Web of Science ®Google Scholar
• Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:2843–2852.
   PubMed Web of Science ®Google Scholar
• Ding L, Hu J, Wang D, et al. Efficacy and safety of first-and second-line drugs to prevent glucocorticoid-induced fractures: a network meta-analysis. J Clin Endocrinol Metab. 2019 Sep 12. dgz023. DOI:10.1210/clinem/dgz023. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–916.
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095–2104.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441.
   PubMed Web of Science ®Google Scholar
• Devogelaer J-P, Adler RA, Recknor C et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol. 2010;37(1):141–148.
   PubMed Web of Science ®Google Scholar
• Oxlund H, Ortoft G, Thomsen JS, et al. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone. 2006;39(2):244–252.
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–3355.
   PubMed Web of Science ®Google Scholar
• Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355–1368.
   PubMed Web of Science ®Google Scholar
• Farahmand P, Marin F, Hawkins F, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int. 2013;24(12):2971–2981.
   PubMed Web of Science ®Google Scholar
• Gurney EP, Nachtigall MJ, Nachtigall LE, et al. The women’s health initiative trial and related studies: 10 years later: a clinician’s view. J Steroid Biochem Mol Biol. 2014;142:4–11.
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24(5):361–379.
   PubMed Web of Science ®Google Scholar
• Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol. 2014;143:207–222.
   PubMed Web of Science ®Google Scholar
• Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994;37(10):1499–1505.
   PubMedGoogle Scholar
• Mok CC, Ying KY, To CH et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double blinded placebo-controlled trial. Ann Rheum Dis. 2011;70(5):778–784.
   PubMed Web of Science ®Google Scholar
• Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996;56(11):1173–1177.
   Google Scholar
• Hall GM, Larbre JP, Spector TD et al. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol. 1996;35(6):568–573.
   PubMedGoogle Scholar
• Crawford BAL, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab. 2003;88(7):3167–3176.
   PubMed Web of Science ®Google Scholar
• Di Somma C, Colao A, Pivonello R, et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing’s disease. Clin Endocrinol (Oxf). 1998;48(5):655–662.
   PubMed Web of Science ®Google Scholar
• Randazzo ME, Grossrubatscher E, Dalino Ciaramella P, et al. Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary. 2012;15(2):193–201.
   PubMed Web of Science ®Google Scholar
• Lasco A, Catalano A, Morabito N, et al. Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis. Osteoporos Int. 2011;22(1):299–303.
   PubMed Web of Science ®Google Scholar
• Tauchmanova L, Guerra E, Pivonello R, et al. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome. J Endocrinol Invest. 2009;32(5):390–394.
   PubMed Web of Science ®Google Scholar
• Adler RA Glucocorticoid-induced osteoporosis: management challenges in older patients. J Clin Densitom. 2019;22(1):20–24.
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MAM, Lin P et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
   PubMed Web of Science ®Google Scholar
• Bultink IEM, Harvey NC, Lalmohamed A, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int. 2014;25(4):1275–1283.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Gaudio A, Eller-Vainicher C, et al. Cortisol secretion, sensitivity, and activity are associated with hypertension in postmenopausal eucortisolemic women. J Clin Endocrinol Metab. 2019;104(10):4441–4448.
   PubMed Web of Science ®Google Scholar
• Morelli V, Polledri E, Mercadante R, et al. The activity of 11β-hydroxysteroid dehydrogenase type 2 enzyme and cortisol secretion in patients with adrenal incidentalomas. Endocrine. 2016;53(3):809–815.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Ramos-Rivera A, Marcus AO, et al. Adrenal hypercortisolism: a closer look at screening, diagnosis, and important considerations of different testing modalities. J Endocr Soc. 2019;3(5):1097–1109.
   PubMed Web of Science ®Google Scholar